KUALA LUMPUR, Dec 18 (Bernama) – Crown Bioscience, a global drug discovery and development services company is expanding its existing translational oncology research capacity by opening a new site in Suzhou, Jiangsu, China.
The site opening increases the company’s services and capacity. It will also become CrownBio’s center of excellence for systems biology and clinical sample testing, according to a statement.
Chief executive officer of CrownBio, Dr. Jean-Pierre Wery said: “The Suzhou site is a direct result of increased customer demand and market dynamics. It will allow us to both support an increased volume of global customer studies and accelerate our bioinformatics goals, which will in turn facilitate the development of the next generation of precision medicine.”
The site will focus on integrating the company’s experience in preclinical and translational research with cutting-edge digital technologies for the discovery of predictive biomarkers and the development of new and companion diagnostics.
CrownBio will enhance its current translational oncology platform by expanding its existing services, and developing additional services, for advanced systems biology, including bioinformatics, big data and machine learning, along with biomarker discovery and clinical sample testing.
Located at the BioBay Science Park, one of the top-ranked biopharmaceutical hubs in China, the center will also bring CrownBio closer contact to regional and global pharmaceutical companies.
Crown Bioscience provides translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. More details at https://www.crownbio.com
-- BERNAMA
-- BERNAMA
No comments:
Post a Comment